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ABSTRACT
The aim of this study was to investigate in vivo antitumor activity of newly synthesized N-sulfonylpyrimidine 
derivatives applied as a single agent and in combination with hyperthermia (43 oC/60 min). Antitumor activity 
was examined for: 1-(p-toluenesulfonyl)cytosine (4H), 1-(p-toluenesulfonyl)cytosine hydrochloride (4HxHCl), 
complex (Zn(II) [1-(p-toluenesulfonyl)cytosine]2) (4K) and 5-bromo-1-(methanesulfonyl)uracil (8H). In the 
study we used transplantable anaplastic mammary carcinoma (AMCa). All experiments were performed on 
10-14-week-old female CBA mice weighing 22-25 g at the time of treatment. The obtained data show that 
N-sulfonylpyrimidine derivatives (4H, 4HxHCl, 4K, 8H) possess antitumor activity. In combination with 
hyperthermia, the highest enhancement was obtained when hyperthermia was applied with 4HxHCl (300 mg/
kg). The antitumor activity of N-sulfonylpyrimidine derivatives was similar or better than the antitumor effect of 
5-fl uorouracil (positive control). These fi ndings provide a good reason for further research of these compounds, 
both in experimental and preclinical studies. 
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Introduction 
A number of recent innovative research approaches, targeting malignant abnormalities 
of tumor cells are under development. However, new derivatives of presently known 
“small molecule” cytotoxic agents, possessing improved properties, such as broader 
activity and lower toxicity, will continue to be an essential part of cancer therapy in the 
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near future. Therefore, a strong need for new “small molecule” cytotoxic agents, with 
improved properties still exists.
Modifi ed nucleosides and nucleic acid bases have been the subject of many studies 
due to their potential antitumor activity (BADAWEY, 1996; HATTORI et al., 1996; HATSE et 
al., 1999). The pyrimidine derivatives that are currently used as fi rst-line chemotherapeutic 
agents for treatment of a wide range of solid tumors are 5-fl uorouracil (5-FU) and 
capecitabine (ISAAC et al., 2002; ASSIKIS et al., 2003). HARADA et al. (1995), and SAKURAI 
et al. (1996) have shown that 5-fl uorouracil, in combination with hyperthermia, has much 
better activity in comparison to 5-fl uorouracil treatment only. A good synergistic effect was 
also obtained when hyperthermia was applied with cisplatin (STOJKOVIĆ and RADAČIĆ, 
2002), dacarbasine and cyclophosphamide (STOJKOVIĆ and RADAČIĆ, 2002), paclitaxel 
(CIVIDALLI et al., 1999) and nicotinamide (EIKESDAL et al., 2001). 
Recently, KAŠNAR et al. (1997), ŽINIĆ et al. (1999; 2003a; 2003b), KAŠNAR-
ŠAMPREC et al. (2005) and GLAVAŠ-OBROVEC et al. (2005a) designed and synthesized 
N-sulfonylpyrimidine derivatives as a new type of sulfonylcyclourea. The N-
sulfonylpyrimidine derivatives showed potent growth inhibitory activity against human 
tumor cell lines in vitro (GLAVAŠ-OBROVAC et al., 2001, 2005a and 2005b). Some of them 
showed the ability to induce apoptosis in treated tumor cells (GLAVAŠ-OBROVAC et al., 
2001) and have strong antiproliferative activity and good selective effect in regard to 
normal cells (SUPEK et al., 2008). These types of nucleic base derivatives were found to 
inhibit DNA, RNA and protein synthesis (ŽINIĆ et al., 2003b; GLAVAŠ-OBROVAC et al., 
2005a), and in vivo studies showed that N-1-sulfonylpyrimidine derivatives have strong 
antitumor activity against mouse mammary carcinoma (PAVLAK et al., 2005a; GLAVAŠ-
OBROVAC, 2005a). 
These novel N-1-sulfonylpyrimidine derivatives represent a valuable contribution 
to the development of new anticancer chemotherapeutic agents capable of improving 
(anti)tumor therapy. With respect to these observations and the positive infl uence of 
hyperthermia on the recently used cytostatic drugs, we investigated the antineoplastic 
activity of these derivatives in combination with local hyperthermia.
Materials and methods
Animals. Mice were obtained from the Ruđer Bošković Institute’s breeding colony. 
During the experiment, three to four animals were kept in a cage. Food and water were 
supplied ad libitum. All experiments were performed on 10-14 week-old female CBA 
mice weighing 22 - 25 g at the time of treatment. Eight to ten animals were used in 
each group per experiment. Animals were treated with examined drugs alone and in 
combination with local hyperthermia. Each experiment was repeated twice. 
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All procedures performed in this study were according to the European document 
entitled “Directive for the Protection of Vertebrate Animals Used for Experimental and 
other Scientifi c Purposes” (86/609/EEC) as well as the Croatian Act on Animal Protection 
in experimental work (NN19/99).
Tumors. In this study we used anaplastic mouse mammary carcinoma (AMCa) arising 
spontaneously in a female CBA mouse and maintained by serial transplantation in syngenic 
recipients (CBA mice) (PAVLAK et al., 2005a). The tumor was transplanted by injection 
of 106 tumor cells (0.02 mL) into the footpad of the right hind leg. Tumor volume was 
measured by caliper and calculated according to the formula A×B×C×π/6 where A, B, C 
represent three orthogonal tumor diameters. The end point of tumor response was tumor 
growth time (TGT) i.e. the time needed for an individual tumor to increase its volume fi ve 
times over the volume at the beginning of the tumor volume measurement. The effect of 
therapy was evaluated by comparing tumor growth time in the treated groups of animals 
versus tumor growth time in the control (untreated) group of animals. 
New agents: N-Sulfonylpyrimidine derivatives. The synthesis of N-sulfonylpyrimidine 
derivatives, by attaching the sulfonyl fragment onto N-1 of pyrimidine bases, was described 
for the fi rst time in its patent (ŽINIĆ et al., 2003a). The compounds were synthesized in 
the Laboratory of Supramolecular and Nucleoside Chemistry, Rudjer Bošković Institute 
(Zagreb, Croatia). 
Antitumor activity was investigated for cytosine derivatives: 1-(p-
toluenesulfonyl)cytosine (4H), 1-(p-toluenesulfonyl)cytosine hydrochloride (4HxHCl) 
and complex (Zn(II) [1-(p-toluenesulfonyl)cytosine]2) (4K) and uracil derivative 5-bromo-
1-(methanesulfonyl)uracil (H8). The structures of investigated N-sulfonylpyrimidine 
derivatives are shown in Figure 1.
Hyperthermia. Local hyperthermia (HT) was given by immersing the tumor-bearing 
leg into a water bath (Heto water bath, Birkerad, Denmark), which gives temperature of 43 
oC. A total heating time of 60 min was applied in our experiments. Hyperthermia treatment 
started when the tumor reached a volume of about 200 mm3 which was usually between 
10 and 16 days after tumor cell implantation into the footpad. All tested compounds were 
administrated 15 min prior to application of hyperthermia.
Treatment. In this work all tested compounds were used alone and with local 
hyperthermia. The treatment groups were as follows: Group I: control/untreated animals 
received vehicle; Group II: animals received 1200 mg/kg of derivative 4H alone; Group 
III: animals received 300 mg/kg of derivative 4HxHCl alone; Group IV: animals received 
300 mg/kg of derivative 4K alone; Group V: animals received 50 mg/kg of derivative 
H8 alone; Group VI: animals received 100 mg/kg of 5FU alone; Group VII: control/HT 
animals received HT alone; Group VIII: animals received 1200 mg/kg of derivative 4H 
with HT; Group IX: animals received 300 mg/kg of derivative 4HxHCl with HT; Group 
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X: animals received 300 mg/kg of derivative 4K with HT; Group XI: animals received 50 
mg/kg of derivative H8 with HT; Group XII: animals received 100 mg/kg of 5-FU with 
HT. 
The doses of new compounds used were chosen according to previous studies 
(PAVLAK et al., 2005a, 2005b). 5-FU was used as a positive control. All test compounds 
were dissolved in distilled water immediately prior to intraperitoneal injection. All 
dissolved compounds were given intraperitoneally according to the body weight of mice, 
i.e. 0.5 mL of solution was given per 25 g of body weight. 
Statistical analysis. All results were presented as arithmetic mean ± standard deviation 
(X ± SD) of TGT. The effect of therapy was evaluated by comparing TGT in the treated 
groups of animals versus TGT in the control (untreated) group of animals. A comparison 
was also made with the positive control group (5-FU) and comparing TGT in the group of 
animals treated with new agents alone, versus TGT in the group of animals treated with 
hyperthermia plus new agents. The T/C ratio was calculated for all treated groups and 
presented as a percentage [(TGT-treated group/TGT-control) × 100].
The results were tested by the ANOVA test for independent samples. The level for 
statistical signifi cance was set at the level of<0.05.
Results 
The results presented in Tables 1 and 2 and in Fig. 2 show antitumor activity of all 
investigated N-sulfonylpyrimidine derivatives applied alone (Table 1) and in combination 
with a local hyperthermia (Table 2). 
Table 1. Antitumor activity of 4H (1-(p-toluenesulfonyl)cytosine), 4HxHCl (1-(p-
toluenesulfonyl)cytosine hydrochloride and complex 4K (Zn(II) [1-(p-toluenesulfonyl)cytosine]2) 




X ± SD (days) Therapy: Control P T/C* (%)
Control/untreated 9.6 ± 1.9 1.0000000 100
4H (1200 mg/kg) 19.0 ± 3.4 0.000017** 198
4HxHCl (300 mg/kg) 17.2 ± 3.1 0.000131** 179
4K (300 mg/kg) 22.4 ± 4.2 0.000002** 233
8H (50 mg/kg) 18.3 ± 2,3 0.000003** 191
5-FU (100 mg/kg) 17.3 ± 4.1 0.000393** 180
**statistically signifi cant; *T represents arithmetic mean TGT of treated animals and C represents arithmetic 
mean TGT of control animals
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From the data shown in Table 1 and Fig. 2 all tested N-sulfonylpyrimidine derivatives 
signifi cantly reduced the speed of mouse tumor growth. TGT was prolonged in all 
examined groups by two or more times compared with the control group (P<0.01). From 
the data shown in Table 2 and Fig. 2 it can be seen that the best effect was achieved 




H C l  x
4H4H xH C l
Zn(4H )2 =  4K
8H
Fig. 1. Structure of N-sulfonylpyrimidine derivative.
Table 2. Antitumor activity of 4H (1-(p-toluenesulfonyl)cytosine), 4HxHCl (1-(p-
toluenesulfonyl)cytosine hydrochloride and complex 4K (Zn(II) [1-(p-toluenesulfonyl)cytosine]2) 
and 8H (5-bromo-1-(methanesulfonyl)uracil) with local hyperthermia (HT) on the tumour growth 
time (TGT) of anaplastic mammary carcinoma 
Treatment(mg/kg)
TGT 
X ± SD (days) Combined therapy: HTP T/C(%)
Control/HT (43 oC) 21.3 ± 1.4 1.0000000 100
4H (1200 mg/kg) + HT 20.9 ± 1.3 0.6672070  98
4HxHCl (300 mg/kg) + HT 24.2 ± 1.7 0.006462** 114
4K (300 mg/kg) + HT 22.3 ± 3.9 0.4049870 105
8H (50 mg/kg) + HT 25,5 ± 6,4 0.0753120 120
5-FU (100 mg/kg) + HT 21.9 ± 5.6 0.5672070 103
** statistically signifi cant; * T represents arithmetic mean TGT of treated animals and C represents arithmetic 
mean TGT of control animals
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TGT in the group of animals treated with 1-(p-toluenesulfonyl)cytosine (4H) was 
about 2 times prolonged in comparison to the control/untreated group (P<0.01) (Table 1, 
Fig. 2). On the other hand, in 4H plus HT (TGT 20.9 ± 1.3 days) no statistical differences 
were found in tumor growth time when compared to the control/HT group (TGT 21.3 ± 
1.4 days) (Table 2, Fig. 2). Derivative 4H showed similar antitumor effect to 5-FU (Table 
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Fig. 2. Antitumor activity of N-sulfonylpyrimidine derivatives (H4, H4xHCl, K4 and H8) and 
local hyperthermia (43 oC) on the growth of anaplastic mammary carcinoma
In the group of animals treated by 1-(p-toluenesulfonyl)cytosine hydrochloride 
(4HxHCl), TGT was also about 1.8 times prolonged in comparison to the control/untreated 
group (P<0.01) and 4HxHCl had similar antitumor activity as the positive control 5-FU 
(Table 1, Fig. 2). Statistically signifi cant results (P<0.05) were obtained in the group 
of animals treated with this derivative and HT (TGT 24.2 ± 1.7 days) in comparison to 
the group of animals treated with HT only (TGT 21.3 ± 1.4 days) (Table 2, Fig. 2). The 
results of combined treatment of 4HxHCl and HT were also statistically signifi cant in 
comparison to the antitumor activity produced by 5-FU plus HT (TGT 21.9 ± 5.6 days) 
(P<0.05) (Table 2, Fig. 2).
The tumor growth time of complex (Zn(II) [1-(p-toluenesulfonyl)cytosine]2) (4K) 
(TGT 22.4 ± 4.2 days) was statistically prolonged compared to TGT in the control/
untreated group (P<0.01). Derivative 4K has also showed some better antitumor activity 
against mouse mammary carcinoma than 5-FU (TGT 17.3 ± 4.1 days), but the result was 
not statistically signifi cant (Table 1 and Fig. 2). Tumor growth time in the protocol with 
4K and HT (TGT 22.3 ± 3.9 days) was similar to tumor growth time in the control/HT 
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group (TGT 21.3±1.4 days) as well as in the group of animals treated with 5-FU and HT 
(TGT 21.9 ± 5.6 days) (Table 2 and Fig. 2). 
TGT in the group of animals treated with 5-bromo-1-(methanesulfonyl)uracil (H8) 
was 18.3 ± 2.3 days, which is 2 times better than in the control/untreated group (TGT 9.6 
± 1.9 days) (P<0.01). Comparing with positive control (5-FU), antitumor effect of this 
derivative was similar to antitumor activity of 5-FU (P>0.05) (Table 1 and Fig. 2). In 
combination with HT, tumor growth time of H8 (TGT 25.5 ± 6.4 days) was prolonged in 
comparing with the group of animals treated with HT only (TGT 21.3 ± 1.4 days) as well 
as in the group of animals treated with 5-FU plus HT (TGT 21.9 ± 5.6 days) (Table 2, Fig. 
2), but there was no statistical signifi cance. 
Discussion
Since N-1-sufonylpyrimidine derivatives showed good cytotoxic activity against 
various human tumour cells in vitro (GLAVAŠ-OBROVAC et al., 2001, 2005a and 2005b) 
as well as promising results in preliminary studies in vivo (PAVLAK et al., 2005a), we 
compared them with antitumor activity of fl uorinated pyrimidine 5-FU which is currently 
used in the therapy of breast cancer (ISAAC et al., 2002; ASSIKIS et al., 2003; ZHANG et 
al., 2008) and with local hyperthermia (HT) because it is known that HT in combination 
with some drugs may improve the antineoplastic effect and reduce the effective dose of 
drugs (CIVIDALLI et al., 1999; EIKESDAL et al., 2001; STOJKOVIĆ and RADAČIĆ, 2002; 
McCORMICK, 2007; KANAYA et al., 2008). 
In this study mouse mammary carcinoma was used because it may serve as a 
good screening model for clinically potential and predictive drug(s) and the applied 
doses for test compounds were chosen on the basis of previous data obtained in LD50 
experiments (McELHINNEY et al., 1989; BIBBY et al., 1993). The antitumor effects of N-
1-sulfonilpyrimidine derivatives were evaluated by comparing the antitumor effect of 
5-FU and combined use of N-1-sulfonilpyrimidine derivatives and HT, applying them 15 
minutes before HT.
Our presented data show that N-1-sulfonilpyrimidine derivatives: 1-(p-
toluenesulfonyl)cytosine (4H), 1-(p-toluenesulfonyl)cytosine hydrochloride 
(4HxHCl), complex (Zn(II) [1-(p-toluenesulfonyl)cytosine]2) (4K) and 5-bromo-1-
(methanesulfonyl)uracil (8H) reduced the growth of AMCa (P<0.01). Tumour growth 
time in the group of animals treated with N-1-sulfonilpyrimidine derivatives was 
prolonged 1.8 (4HxHCl), 1.9 (8H) 2.0 (4H) and 2.3 (4K) times in comparison to control 
group (P<0.01) (Table 1). 
When comparing antitumor activity of N-sulfonylpyrimidine derivatives (4H, 
4HXHCl, 4K and 8H) with antitumor activity of 5-FU (positive control), it can be seen 
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that the antitumor activity of these derivatives was similar to the antitumor activity of 
5-FU (Table 1, Fig. 2). 
Tumour growth time in the group of animals treated with HT was longer than in the 
control/untreated group (P<0.01). Antitumor activity of HT is in agreement with the data 
of other authors achieved with different tumour models (RADAČIĆ, 1995; STOJKOVIĆ 
and RADAČIĆ, 2002). Tumour growth time in the group of animals treated with N-1-
sulfonilpyrimidine derivatives plus HT was prolonged from 2.1 to 2.7 times in comparison 
to the control/untreated group. 
The best antitumor effect of the tested derivatives applied with hyperthermia was 
obtained in the group of animals treated with 4HxHCl plus HT. A statistically signifi cant 
difference was found in the group of animals treated with 4HxHCl alone and with 4HxHCl 
plus HT (P<0.05) (Table 2, Fig. 2). The additive effect between 4HxHCl plus HT could 
be explained by the adequate time interval between administration of derivatives 4HxHCl 
plus HT, which was not found between other derivatives (4H, 4K and 8H) applied with 
HT. The importance of the infl uence of the time interval between drug administration and 
application of HT was demonstrated in different antineoplastic drugs applied by some 
other authors (CIVIDALLI et al., 2000; RAU et al., 2000; PASSETO et al., 2008). 
The antitumor effect of 5-FU in combination with HT was also much better in 
comparison to 5-FU treatment only, which corresponds to the results of some other authors 
(HARADA et al., 1995). When comparing the antitumor activity of 5-FU and HT with the 
antitumor activity of derivatives applied with HT, statistically signifi cant differences in 
TGT were found in the group of animals treated with 4HxHCl plus HT in comparison 
with the TGT of 5-FU plus HT. 
On the basis of the present results, it may be concluded, that new N-1-sulfonylpyrimidine 
derivatives are promising antitumor agents with antineoplastic activity. Hyperthermia in 
combination with 4HxHCl derivative may enhance the antitumor activity, which may be 
explained by the adequate time interval between administration of derivatives 4HxHCl 
plus HT, which was not found between the other derivatives (4H, 4K and 8H) applied 
with HT.
It may be concluded that our results obtained with N-sulfonylpyrimidine derivatives 
are similar to those obtained with 5-FU. However, while 5-FU, a clinically used cytostatic 
drug, has serious side effects, in our study no side effects were observed. 
Therefore, further research on new N-sulfonylpyrimidine derivatives and 
hyperthermia, as well as new compounds with other modalities is a valuable contribution 
to the development of new anticancer chemotherapeutic agents.
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SAŽETAK
Cilj rada bio je istražiti protutumorski učinak novosintetiziranih N-sulfonil-derivata pirimidinskih 
nukleobaza i hipertermije (43 oC/60 min) na rast anaplastičnoga mamarnoga karcinoma. Protutumorski 
učinak ispitan je u sljedećih N-sulfonil-pirimidinskih derivata: 1-(p-toluensulfonil)citozina (4H), 1-(p-
toluensulfonil)citozin hidroklorida (4HxHCl), kompleksa (Zn(II) [1-(p-toluensulfonil)citozin]2) (4K) i 5-
brom-1-(metansulfonil)uracila (8H). Dobiveni rezultati upućuju na protutumorsko djelovanje svih pretraženih 
N-sulfonil-pirimidinskih spojeva (4H, 4HxHCl, 4K, 8H). U odnosu na pozitivnu kontrolu (5-fl uorouracil) 
pretraživani derivati pokazali su podjednako ili čak nešto bolje djelovanje od 5-fl uorouracila. Rezultati 
ispitivanja združenoga djelovanja derivata i hipertermije upućuju na značajniji protutumorski učinak 4HxHCl 
(300 mg/kg) i hipertermije u odnosu na pojedinačni učinak. 
Ključne riječi: hipertermija, mamarni karcinom miša, N-sulfonil-derivati pirimidinskih nukleobaza 
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